Open Access

SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma

  • Authors:
    • Weiguo Zhang
    • Junli Fan
    • Qiang Chen
    • Caipeng Lei
    • Bin Qiao
    • Qin Liu
  • View Affiliations

  • Published online on: March 12, 2018     https://doi.org/10.3892/ol.2018.8235
  • Pages: 7028-7036
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overdue treatment and prognostic evaluation lead to low survival rates in patients with lung adenocarcinoma (LUAD). To date, effective biomarkers for prognosis are still required. The aim of the present study was to screen differentially expressed genes (DEGs) as biomarkers for prognostic evaluation of LUAD. DEGs in tumor and normal samples were identified and analyzed for Kyoto Encyclopedia of Genes and Genomes/Gene Ontology functional enrichments. The common genes that are up and downregulated were selected for prognostic analysis using RNAseq data in The Cancer Genome Atlas. Differential expression analysis was performed with 164 samples in GSE10072 and GSE7670 datasets. A total of 484 DEGs that were present in GSE10072 and GSE7670 datasets were screened, including secreted phosphoprotein 1 (SPP1) that was highly expressed and DEGs ficolin 3, advanced glycosylation end‑product specific receptor (AGER), transmembrane protein 100 that were lowly expressed in tumor tissues. These four key genes were subsequently verified using an independent dataset, GSE19804. The gene expression model was consistent with GSE10072 and GSE7670 datasets. The dysregulation of highly expressed SPP1 and lowly expressed AGER significantly reduced the median survival time of patients with LUAD. These findings suggest that SPP1 and AGER are risk factors for LUAD, and these two genes may be utilized in the prognostic evaluation of patients with LUAD. Additionally, the key genes and functional enrichments may provide a reference for investigating the molecular expression mechanisms underlying LUAD.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang W, Fan J, Chen Q, Lei C, Qiao B and Liu Q: SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma. Oncol Lett 15: 7028-7036, 2018
APA
Zhang, W., Fan, J., Chen, Q., Lei, C., Qiao, B., & Liu, Q. (2018). SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma. Oncology Letters, 15, 7028-7036. https://doi.org/10.3892/ol.2018.8235
MLA
Zhang, W., Fan, J., Chen, Q., Lei, C., Qiao, B., Liu, Q."SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma". Oncology Letters 15.5 (2018): 7028-7036.
Chicago
Zhang, W., Fan, J., Chen, Q., Lei, C., Qiao, B., Liu, Q."SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma". Oncology Letters 15, no. 5 (2018): 7028-7036. https://doi.org/10.3892/ol.2018.8235